Global Alliance for Tb Drug Development
Also known as Tb Alliance
Global Alliance for Tb Drug Development reported $63.7 million in revenue and $61.5 million in expenses for calendar year 2024. Of every $100 it spent, $88.47 went to program services, $9.32 to management and general costs and $2.21 to fundraising. Its largest source of revenue was contributions and grants: 82.7% of the total. Government grants made up 56.1%. The highest compensation it reported for one person was $1,052,936 (PRESIDENT/CEO). 42 people received more than $100,000 in reportable compensation. Revenue fell 64% between 2019 and 2024. Source: Form 990, 2024.
Where $100 of spending went
Calendar year 2024 · Form 990, Part IX, line 25 · total expenses $62MFor context, the median across 169 covered medical research charities: $87.02 programs, $12.87 management, $0.11 fundraising (medians computed separately, so they may not sum to $100).
Where $100 of revenue came from
Calendar year 2024 · Form 990, Part VIII · total revenue $64MThe 990 scorecard · same measures for every charity, no grades
| Measure | 2024 | Median |
|---|---|---|
| Program services Part IX 25(B) ÷ 25(A) | 88.5% | 83.9% |
| Management & general Part IX 25(C) ÷ 25(A) | 9.3% | 12.4% |
| Fundraising Part IX 25(D) ÷ 25(A) | 2.2% | 0.1% |
| Fundraising cost per $1 of contributions Part IX 25(D) ÷ Part VIII 1h | $0.03 | $0.01 |
| Contributions & grants share of revenue Part VIII 1h ÷ 12 | 82.7% | 72.7% |
| Government grants share of revenue Part VIII 1e ÷ 12 | 56.1% | 0.0% |
| Program service revenue share Part VIII 2g ÷ 12 | 0.0% | 5.8% |
| Highest reported compensation Part VII-A, columns D–F | $1,052,936 | $628,890 |
| Highest compensation as share of expenses Part VII-A ÷ Part IX 25(A) | 1.71% | 1.94% |
| People paid over $100,000 Part VII, line 2 | 42 | 18 |
| Net assets, in months of expenses Part X 33(B) ÷ monthly expenses | 34.4 | 13.3 |
| Independent voting board members Part VI 1a–1b | 11 of 12 | 93.8% |
A median is context, not a target: hospitals, universities, food banks and grantmakers spend in very different ways. What these measures can and can't tell you.
What the money paid for, in its own words
2024 · Form 990, Part III · the three largest programs by expenseResearch and development - tb alliance is a not-for-profit product development partnership (pdp), uniquely positioned to leverage a global network of public and private partners to most efficiently advance tb Drug Development. A pdp builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. Pdps retain direct management oversight of their projects, though much of the laboratory and clinical work is done through external research facilities and contractors. We combine the research and development…
Public affairs and policy - tb alliance maintains critical alliances with public and private organizations to raise awareness about tuberculosis ("tb") and advocate for public and private involvement in research for the public good. Specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably for those areas most in need while encouraging the private sector on the development of these medicines. Tb alliance continues to pursue an explicit commitment to our "aaa mandate" - that all new products will be adopted, available and…
Business development - tb alliance negotiates, implements and manages agreements with public and private organizations worldwide and does so by adhering to sound business practices while ensuring the public good. Specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably to those areas most in need while encouraging the private sector to help develop new medicines for tb indications
Highest reported compensation
2024 · Form 990, Part VII, Section A · roles as filed; names are in the filing, not here| Role | From this org | From related orgs | Other | Total |
|---|---|---|---|---|
| PRESIDENT/CEO Director/trustee, officer, 45.0 hrs/week | $939,703 | $0 | $113,233 | $1,052,936 |
| SR. VP, CHIEF SCIENTIFIC OFFICER Key employee, 45.0 hrs/week | $565,207 | $0 | $118,405 | $683,612 |
| SR. VP, RESEARCH & DEVELOPMENT Key employee, 45.0 hrs/week | $580,925 | $0 | $93,318 | $674,243 |
| VP, CHIEF MEDICAL OFFICER Key employee, 45.0 hrs/week | $497,709 | $0 | $86,293 | $584,002 |
| SECRETARY/CAO Officer, 45.0 hrs/week | $470,044 | $0 | $71,098 | $541,142 |
| SR. VP, BUSINESS DEVELOPMENT Highest compensated employee, 45.0 hrs/week | $448,954 | $0 | $87,286 | $536,240 |
| TREASURER/CFO Officer, 45.0 hrs/week | $421,854 | $0 | $104,371 | $526,225 |
| SR. VP, MARKET ACCESS Highest compensated employee, 45.0 hrs/week | $417,509 | $0 | $103,720 | $521,229 |
42 people received more than $100,000 in reportable compensation from Global Alliance for Tb Drug Development (Part VII, line 2). Compensation of current officers, directors and key employees totaled $4.5M (Part IX, line 5).
6 years of filings
Form 990, Parts I, VII, IX and X · each row is that year's own filing, linkedGovernance answers, as filed
2024 · the organization's own yes/no answers; explanations, if any, are in Schedule O of the filing · what each means- Voting board members, and how many are independent Part VI, lines 1a–1b12 · 11 independent
- Audited financial statements Part XII 2bYes
- Conflict-of-interest policy Part VI 12aYes
- Whistleblower policy Part VI 13Yes
- Document retention policy Part VI 14Yes
- Independent process for top executive pay Part VI 15aYes
- Board given the 990 before filing Part VI 11aYes
- Family or business ties among insiders Part VI 2No
- Aware of a significant diversion of assets Part VI 5No
- Excess benefit transaction with an insider Part IV 25aNo
- Loans to or from insiders outstanding Part IV 26No
- Lobbying, or a 501(h) election in effect Part IV 4No
- Over $15,000 of professional fundraising services Part IV 18No
- Over $10,000 of activity outside the U.S. Part IV 14bYes
- Employees Part I, line 550
- Volunteers Part I, line 611
Largest outside contractors
2024 · Form 990, Part VII, Section B · businesses only| PPD DEVELOPMENT LP Global cro | $4,305,665 |
| WUXI APPTEC (HONGKONG) LIMITED Integrated r&d services | $3,501,842 |
| CERBA RESEARCH NV Lab costs | $2,778,060 |
| CLININVENT RESEARCH PVT LTD Drug manufacturing / testing | $1,999,500 |
| GLAXOSMITHKLINE INVESTIGACION External mini portfolios | $1,600,000 |
Individuals listed as contractors are left out. 75 contractors were paid more than $100,000 in all.
Private foundation grants it received
3 private foundations reported grants to Global Alliance for Tb Drug Development totaling $17M on their tax year 2023 Form 990-PF returns. See which foundations, on WHOFUNDS.
Source: WHOFUNDS open grant graph, matched from Form 990-PF Part XV.
Correct a figure or respond
Every number above is copied from Global Alliance for Tb Drug Development's own Form 990. If one doesn't match the filing, that's our error and we'll fix it. If you work for Global Alliance for Tb Drug Development, you can publish a response that is linked from this page.
Share or embed this breakdown
Of every $100 Global Alliance for Tb Drug Development spent in 2024, $88.47 went to programs. The full breakdown, from its IRS Form 990:
Embed on your site
Similar-sized charities in this cause
- The V FoundationCary, NC · revenue $62M · programs 86.0% · FY2025
- Stanley Manne Childrens Research InstituteChicago, IL · revenue $65M · programs 56.7% · FY2025
- Alzheimer's Disease Research FoundationWellesley Hills, MA · revenue $57M · programs 92.1% · 2025
- Affinity Partners NetworkJamesburg, NJ · revenue $67M · programs 100.0% · FY2025
- Hennepin Healthcare Research InstituteMinneapolis, MN · revenue $55M · programs 92.2% · 2024
All medical research charities · Largest charities in New York
Questions people ask
How much of Global Alliance for Tb Drug Development's spending goes to programs?
In calendar year 2024, Global Alliance for Tb Drug Development reported that 88.5% of its $61.5 million in expenses went to program services, 9.3% to management and general and 2.2% to fundraising (Form 990, Part IX).
How much does Global Alliance for Tb Drug Development pay its top executive?
The largest total compensation Global Alliance for Tb Drug Development reported for one person in calendar year 2024 was $1,052,936, for the role of PRESIDENT/CEO (Form 990, Part VII, including compensation from related organizations and other compensation).
Where does Global Alliance for Tb Drug Development get its money?
Of $63.7 million in revenue in calendar year 2024, 82.7% came from contributions and grants (including 56.1% from government grants) and 0.0% from program service revenue (Form 990, Part VIII).
Is Global Alliance for Tb Drug Development a registered charity?
The IRS lists EIN 13-4128413 as a 501(c)(3) organization (publicly supported organization (170(b)(1)(a)(vi))), and its records show contributions as tax-deductible. Form 990 filings on record here cover tax years 2019, 2020, 2021, 2022, 2023, 2024. A filing shows what the organization reported; it doesn't by itself show whether a program works.
Sources
- 2024: Form 990 for calendar year 2024, object 202542969349302084 · read the filing · XML
- 2023: Form 990 for calendar year 2023, object 202412779349301201 · read the filing
- 2022: Form 990 for calendar year 2022, object 202333059349302318 · read the filing
- 2021: Form 990 for calendar year 2021, object 202222929349300322 · read the filing
- 2020: Form 990 for calendar year 2020, object 202102879349300740 · read the filing
- 2019: Form 990 for calendar year 2019, object 202023019349301722 · read the filing
All filings for EIN 13-4128413: ProPublica Nonprofit Explorer · IRS Tax Exempt Organization Search. Figures are as the organization reported them; we have not audited them.